Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteopenia.

G R Mundy1

  • 1Department of Medicine, University of Texas Health Science Center, San Antonio.

Disease-A-Month : DM
|October 1, 1987
PubMed
Summary
This summary is machine-generated.

Osteopenia causes 1.3 million fractures annually in the US, costing billions. Prevention through diet, exercise, and hormone therapy is key, as bone loss mechanisms remain unclear.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.

Leukemia·2009
Same author

Locally delivered lovastatin nanoparticles enhance fracture healing in rats.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2007
Same author

Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2006
Same author

MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Bone·2004
Same author

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro.

The Journal of clinical investigation·2003
Same author

Osteoporosis: pathophysiology and non-pharmacological management.

Best practice & research. Clinical rheumatology·2002
Same journal

Disturbances due to cold.

Disease-a-month : DM·2026
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
See all related articles

Area of Science:

  • Gerontology
  • Bone Metabolism
  • Public Health

Background:

  • Osteopenia in the elderly leads to 1.3 million fractures yearly in the US, with $6-10 billion in acute care costs.
  • Pathophysiology of bone loss in osteoporosis remains largely unknown despite advances in understanding risk factors.
  • Noninvasive bone mineral density measurements from the 1980s are controversial and not suitable for mass screening.

Purpose of the Study:

  • To review the current understanding of osteopenia and osteoporosis in the elderly.
  • To highlight the economic burden and clinical challenges associated with age-related bone loss.
  • To emphasize the importance of prevention strategies for maintaining bone mass.

Main Methods:

  • Literature review of studies on osteopenia, osteoporosis, and bone metabolism.

Related Experiment Videos

  • Analysis of economic data related to osteoporotic fractures.
  • Discussion of diagnostic limitations and therapeutic approaches.

    • Main Results:

    • Osteoporosis is characterized by irreversible trabecular bone thinning and fragmentation in advanced stages.
    • Current noninvasive bone density assessments have limitations for routine clinical use and screening.
    • Effective prevention strategies include estrogen therapy, adequate calcium intake, and lifelong physical activity.

    Conclusions:

    • Differentiating osteoporosis from other osteopenic conditions (e.g., osteomalacia, hyperparathyroidism, myeloma) is crucial due to differing prognoses and treatments.
    • Prevention is the most effective approach to managing osteopenia and osteoporosis.
    • A multi-faceted approach involving diet, exercise, and timely medical intervention is essential for bone health in aging populations.